ArriVent BioPharma (AVBP) Cash & Equivalents (2023 - 2026)

ArriVent BioPharma has disclosed Cash & Equivalents across 4 years of filings, most recently posting $326.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $326.4 million, up 58.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $326.4 million (up 58.83% YoY), and the FY2025 annual result was $45.5 million, down 34.29% from the prior year.
• Cash & Equivalents came in at $326.4 million for Q1 2026 at ArriVent BioPharma, up from $45.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $326.4 million in Q1 2026 to a low of $45.5 million in Q4 2025.
• The 4-year median for Cash & Equivalents is $164.9 million (2023), against an average of $189.5 million.
• Across the five-year window, Cash & Equivalents tumbled 62.24% in 2025 and soared 58.83% in 2026, its largest moves.
• ArriVent BioPharma's Cash & Equivalents stood at $124.3 million in 2023, then sank by 44.25% to $69.3 million in 2024, then sank by 34.29% to $45.5 million in 2025, then soared by 616.73% to $326.4 million in 2026.
• The last three Cash & Equivalents figures came in at $326.4 million (Q1 2026), $45.5 million (Q4 2025), and $112.7 million (Q3 2025), per Business Quant data.